Mersana Therapeutics, Inc. (NASDAQ:MRSN) a biotechnology company, is reporting second quarter earnings results on Friday 7th August 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.3 per share.
For the full year, analysts predict revenues of $ 0.79 million, while looking forward to loss of $ 1.22 per share.
Previous Quarter Performance
Mersana Therapeutics, Inc. posted loss for the first quarter of $ 0.35 per share, from the revenue of $ 0.01 million. The quarterly revenues lowered 99.98 percent compared with the same quarter last year. Street analysts expected Mersana Therapeutics, Inc. to report loss of $ 0.37 per share on revenue of $ 0.39 million for the first quarter. The bottom line results beat street analysts by $ 0.02 or 5.41 percent, at the same time, top line results fell short of analysts by $ 0.38 million or 97.44 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Mersana Therapeutics, Inc.
Stock Performance
The company has a market capital of $ 1.40 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”MRSN” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Mersana Therapeutics, Inc. will be hosting a conference call at 8:00 AM eastern time on 7th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.mersana.com
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications.
